Deals & Cases
MLLStart! advised Clinical Research Ventures (CR Ventures) in its investment into BioVersys AG in a Series C financing round
Start-up desk MLLStart! advised Clinical Research Ventures (CR Ventures), a global life-science investor with a focus on companies entering Phase I or II clinical trials based in Boston, USA, in its investment in a Series C financing round of BioVersys AG, a privately-held clinical-stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation.
The closing of the Series C financing round will allow BioVersys to initiate first Phase II clinical trials of BV100, which addreses serious infections, and BVL-GSK098 and the preclinical development of BV200.
The team was led by Karin Oberlin (Partner, Transactions/MLLStart!) and included Melanie Müller (Senior Associate, Transaction/MLLStart!).
